Eiger BioPharmaceuticals

Eiger BioPharmaceuticals - Biopharmaceutical company developing a diverse portfolio of well-characterized drugs for orphan diseases.

Industries

Biotechnology

Headquarters

Palo Alto, United States

Stage

Post IPO Debt

Employees

11-50

Links

Org chart

David Apelian

Interim CEO

Collapse

Christopher Kurtz

Chief Technical Officer

Eldon Mayer, III

EVP, Chief Commercial Officer

Ingrid Choong

SVP, Clinical Development

Colleen Craig

VP, Metabolic Diseases

Ashwini Kadam

Head of Analytical Development and QC

Henk Kocken

Vice President Quality Assurance

Sherri Hubby

Senior Director, GCP QA

Bill Kachioff

Chief Financial Officer

James Vollins

General Counsel, Chief Compliance Officer & Corporate Secretary

Teams

View all

Leadership Team

4 members

CEO and Executive Team

3 members

Board of Directors

8 members

Founding Team

1 members

Discover similar companies

Fortress Biotech

New York, United States · Post IPO Equity

UNITY Biotechnology

San Francisco, United States · Post IPO Debt

SCYNEXIS

Jersey City, United States · Post IPO Equity

Coherus BioSciences

Redwood City, United States · Post IPO Debt

Galectin Therapeutics

Norcross, United States · Post IPO Debt

First Wave BioPharma

NY, United States · Post IPO Equity

Super League Gaming

Santa Monica, United States · Post IPO Equity

MedRhythms

Boston, United States · Series B

Halo Labs

Philadelphia, United States · Series C

Exicure

Skokie, United States · Post IPO Equity

Caladrius Biosciences

Basking Ridge, United States · IPO

Capricor Therapeutics

Beverly Hills, United States · Post IPO Equity

The Org
helps you hire
great candidates

It takes less than ten minutes to set up your company page.
It’s free to use - try it out today.